Matilda Biotech (002932.SZ) plans to acquire 100% of Wuhan Bicail's shares and is expected to constitute a major asset restructuring

Zhitong Finance App News, Mingde Biotech (002932.SZ) issued an announcement. The company and Lanfan Medical Co., Ltd. (hereinafter referred to as the “counterparty” or “Blue Sail Medical”) signed a “Share Acquisition Intent Agreement”. The two parties reached a framework agreement on the company's transaction to acquire 100% of the shares of Wuhan Bicyle Rescue Products Co., Ltd. (hereinafter referred to as the “target company”) in cash, and clarified matters such as the subsequent acquisition work arrangements and the signing of a formal acquisition agreement between the two parties. According to preliminary estimates, the transaction is expected to constitute a major asset restructuring as stipulated in the “Administrative Measures on Major Asset Restructuring of Listed Companies”.

The target company is an enterprise that introduced the International First Aid (FirstAid) concept and technology earlier. It is mainly engaged in emergency rescue business with a comprehensive layout of emergency equipment, emergency items, and emergency services with first aid kits as the core.

This transaction is an important layout of the company based on focusing on the strategic development needs of the critical care business sector. As a leading enterprise in the field of emergency protection, the target company has been serving high-quality industrial customers at home and abroad for a long time, and is actively expanding to the household consumer side. The company and the target company have significant complementarity in terms of product line and customer base: the company's current smart diagnosis business is mainly aimed at medical institutions, while the target company has a deep foundation in industrial emergency protection and supermarket channels, and is actively expanding home users. This integration will strongly promote the expansion of the company's integrated emergency and critical care business from medical institutions to industrial and family scenarios, build a “diagnosis-protection-treatment” collaborative ecosystem, further enhance the company's asset quality and profit level, and consolidate and enhance the company's market position and overall competitiveness in the critical field.